Centuple Global Limited
BSE: CHECKPOINT · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Centuple Global Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Start your research today
Unlock AI insights, financials, peers and live data on Centuple Global Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹12 Cr
TTM · standalone
NET PROFIT
₹0.09 Cr
TTM · standalone
EPS
₹0.19
TTM · standalone
RETURN ON EQUITY
16.7%
TTM · standalone
P/E
216.6x
Q1 FY26 · standalone
EV/EBITDA
165.6x
Q1 FY26 · standalone
EBITDA MARGIN
0.9%
TTM · standalone
NET PROFIT MARGIN
0.2%
Q4 FY26 · standalone
DEBT TO EQUITY
3.3x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Centuple Global LimitedCHECKPOINT | ₹18 Cr | 216.58 | 165.64 | 1075.7% | 0.9% | 16.7% | 19.6% | -36.0% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q1 FY26
Financials
Centuple Global Limited
BSE: CHECKPOINT · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Centuple Global Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Start your research today
Unlock AI insights, financials, peers and live data on Centuple Global Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹12 Cr
TTM · standalone
NET PROFIT
₹0.09 Cr
TTM · standalone
EPS
₹0.19
TTM · standalone
RETURN ON EQUITY
16.7%
TTM · standalone
P/E
216.6x
Q1 FY26 · standalone
EV/EBITDA
165.6x
Q1 FY26 · standalone
EBITDA MARGIN
0.9%
TTM · standalone
NET PROFIT MARGIN
0.2%
Q4 FY26 · standalone
DEBT TO EQUITY
3.3x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q1 FY26